Biosimilar Clinical Trials: How Can Regulators Determine Waiver Early In Development?

 
• By Derrick Gingery
  
waiver
OTBB Director Sarah Yim said regulators need a framework for determining when comparative efficacy trials are necessary for biosimilar approval. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics